Exploring the effects and mechanism of peony pollen in treating benign prostatic hyperplasia

被引:0
|
作者
Mu, Jun [1 ]
Wu, Junsheng [1 ]
Duan, Linrui [1 ]
Yang, Qian [2 ]
Liu, Xiaoting [1 ]
Bai, Huixin [1 ]
Xie, Yanhua [1 ]
Li, Jie [2 ]
Wang, Siwang [1 ]
机构
[1] Northwest Univ, Coll Life Sci, Biomed Key Lab Shaanxi Prov, Xian 710069, Peoples R China
[2] Air Force Med Univ, Sch Pharm, Dept Chinese Mat Med & Nat Med, Xian 710032, Peoples R China
关键词
Peony pollen; Benign prostatic hyperplasia; Network pharmacology; Target prediction; Molecular docking; URINARY-TRACT SYMPTOMS; PLANT FLAVONE; CYCLOOXYGENASE-2; WOGONIN; EPIDEMIOLOGY; SUPPRESSION; CHRYSIN;
D O I
10.1016/j.heliyon.2023.e22212
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Paeonia suffruticosa is widely cultivated globally due to its medicinal and ornamental value. Peony pollen (PP) is commonly used in Chinese folk medicine to make tea to treat benign prostatic hyperplasia (BPH), but its molecular mechanism against BPH is yet to be comprehended. The objective of this research was to experimentally verify the effect of PP in the treatment of BPH and to preliminarily reveal its mechanism of action on BPH using network pharmacology methods. The results revealed that PP could decrease prostate volume and prostate index, serum testos-terone (T), dihydrotestosterone (DHT), and estradiol (E2) levels. Moreover, it could improve prostate tissue structure in BPH model animals as well. Additionally, database searches and disease target matching revealed 81 compounds in PP. Of these, 3, 7, 8, 2 '-tetrahydroxyflavone, Chrysin, Wogonin, Limocitrin, and Sexangularetin were the top five compounds associated with the therapeutic effects of BPH. Furthermore, 177 therapeutic targets for BPH were retrieved from databases of Swiss Target, DisGeNET, Drugbank, Genecards, OMIM, TTD, and Uniprot. In contrast, core targets AKT1, EGFR, IL6, TNF, and VEGFA were obtained by PPI network diagram. Molecular docking also showed that the main efficacy components and potential core targets in PP had good binding capacity. Gene ontology (GO) and Kyoto Encyclopedia of Genes and Genomics (KEGG) analysis established that the effect of PP in BPH therapy was mainly through regulating the expression levels of protein kinase B on phosphatidylinositol 3-kinase and phosphatidylinositol 3-kinase-protein kinase B pathways. Additionally, Western blot experiments also exhibited a significant elevation in the activated PI3K and AKT proteins in the model (Mod) group relative to the control (Con) group, and the expression of these activated proteins was significantly reduced after PP administration. In summary, this research provides a scientific basis for employing PP to treat BPH, preliminarily reveals its mechanism of action and potential targets, and lays the foundation for further research and development.
引用
收藏
页数:11
相关论文
共 50 条
  • [21] The underlying mechanism of metabolic syndrome on benign prostatic hyperplasia and prostate volume
    Xia, Bo-Wen
    Zhao, Si-Cong
    Chen, Zong-Ping
    Chen, Chao
    Liu, Tian-Shu
    Yang, Fan
    Yan, Yong
    PROSTATE, 2020, 80 (06) : 481 - 490
  • [22] Outcomes of Prostatic Artery Embolization for Treating Benign Prostatic Hyperplasia Symptoms: A Prospective Single-Center Study
    Delazar, Sina
    Azadnajafabad, Sina
    Firouznia, Kavous
    Nowroozi, Mohammad Reza
    Amini, Erfan
    Fotouhi, Maryam
    Ghanaati, Hossein
    HEALTH SCIENCE REPORTS, 2025, 8 (03)
  • [23] Benign prostatic hyperplasia
    Clarke, HS
    AMERICAN JOURNAL OF THE MEDICAL SCIENCES, 1997, 314 (04) : 239 - 244
  • [24] Metabolic Syndrome and Benign Prostatic Hyperplasia/What Component of Metabolic Syndrome Is Related to Benign Prostatic Hyperplasia?
    Tarim, Bahar Arican
    Camur, Emre
    Kavukoglu, Ovunc
    Kosemen, Mete
    Ozgur, Yasemin
    Narter, Kamil Fehmi
    JOURNAL OF UROLOGICAL SURGERY, 2023, 10 (03): : 194 - 198
  • [25] Benign Prostatic Hyperplasia
    Paolone, David R.
    CLINICS IN GERIATRIC MEDICINE, 2010, 26 (02) : 223 - +
  • [26] Benign prostatic hyperplasia
    Shabbir, M
    Mumtaz, FH
    JOURNAL OF THE ROYAL SOCIETY FOR THE PROMOTION OF HEALTH, 2004, 124 (05): : 222 - 227
  • [27] Benign prostatic hyperplasia
    Thiounn, N
    Flam, T
    Conquy, S
    Zerbib, M
    Debre, B
    SEMAINE DES HOPITAUX, 1996, 72 (11-12): : 357 - 361
  • [28] Inhibitory effect of rape pollen supercritical CO2 fluid extract against testosterone-induced benign prostatic hyperplasia in rats
    Yang, Bi-Cheng
    Jin, Li-Li
    Yang, Yi-Fang
    Li, Kun
    Peng, Dan-Ming
    EXPERIMENTAL AND THERAPEUTIC MEDICINE, 2014, 8 (01) : 31 - 37
  • [29] Effects of algerian nettle (Urtica dioica L.) on benign prostatic hyperplasia and their mechanism of action elucidation: in vivo and in silico approaches
    Bougueroua, Karima
    Boufadi, Mokhtaria Yasmina
    Latreche, Batoul
    Celik, Ismail
    Gonzalez, Miguel Guerrero
    Bounoua, Amina Doubbi
    Bouras, Samir
    Eissa, Ahmed
    Zoeir, Ahmed
    NATURAL PRODUCT RESEARCH, 2024, 38 (22) : 4017 - 4027
  • [30] Benign prostatic hyperplasia
    Chughtai, Bilal
    Forde, James C.
    Thomas, Dominique Dana Marie
    Laor, Leanna
    Hossack, Tania
    Woo, Henry H.
    Te, Alexis E.
    Kaplan, Steven A.
    NATURE REVIEWS DISEASE PRIMERS, 2016, 2 : 1 - 15